Free Trial
LON:FTV

Foresight VCT 9/25/2025 Earnings Report

Foresight VCT logo
GBX 0.66 -64.85 (-99.00%)
As of 05/8/2026

Foresight VCT EPS Results

Actual EPS
GBX 0.90
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Foresight VCT Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Foresight VCT Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Foresight VCT Earnings Headlines

NNVC FDA = New Momentum Wave!
NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for NV-387, its antiviral candidate targeting measles - a disease with no approved antiviral treatment and rising global case counts. Beyond measles, NV-387 is designed as a broad-spectrum platform targeting RSV, influenza, coronaviruses, and Mpox, giving NNVC exposure to multiple large markets as Phase II trials advance. The designation unlocks faster development timelines, financial incentives, and potential market exclusivity.tc pixel
See More Foresight VCT Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Foresight VCT? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Foresight VCT and other key companies, straight to your email.

About Foresight VCT

Foresight VCT (LON:FTV) Plc is a private equity and buyouts firm, venture capital trust and managed by Foresight Group. This fund invests in SME, later stage growth capital opportunities across a range of sectors. It engages in investments in unquoted or AIM-listed companies in the United Kingdom. It invests in technology companies in United Kingdom.

View Foresight VCT Profile